MedPath

Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)

Phase 1
Completed
Conditions
Fungal Infection
Interventions
Registration Number
NCT03336502
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of posaconazole intravenous solution in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study. The primary hypothesis is to evaluate the pharmacokinetic parameters of intravenous (IV) posaconazole (POS) solution in Chinese participants at high risk of invasive fungal infections and determine the percentage of Chinese participants who reach steady-state concentration averages of POS in blood plasma of 500 ng/ml and higher. Two subgroups were evaluated: Subgroup 1 from serial PK blood draw sampling and Subgroup 2 from sparse limited PK blood draw sampling.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Chinese participant
  • Female of reproductive potential with a serum of beta human chorionic gonadotropin (β-hCG) level consistent with a nongravid state and agree and/or have their partner use 2 acceptable methods of birth control throughout the study
  • Body Mass Index (BMI) >=15 and <=30 kg/m^2
  • Have a central line catheter or peripherally central venous catheter in place
  • Anticipated or documented prolonged neutropenia and likely to last for at least 7 days due to: a) standard intensive chemotherapy, anthracycline-based or other accepted regimen (excluding any investigational agent) for a new diagnosis of acute myelogenous leukemia (AML); b)chemotherapy for AML in first relapse; or c) therapy for myelodysplastic syndromes in transformation to AML or other diagnoses of secondary AML (therapy related, antecedent hematological disorders) other than chronic myelogenous leukemia in blast crisis
  • Free from any clinically significant disease other than the primary hematologic disease that would interfere with administration of study medication or study evaluations
  • Able to tolerate central IV solution
Read More
Exclusion Criteria
  • Pregnant, intends to become pregnant during the study, or has been nursing
  • Mentally or legally incapacitated, has significant emotional problems, or has clinically significant psychiatric disorder over the last 5 years
  • Received systemic antifungal therapy (oral, intravenous, or inhaled) within 30 days of study enrollment for reasons other than antifungal prophylaxis
  • Known or suspected invasive or systemic fungal infection
  • Taken posaconazole within 10 days prior to study enrollment
  • Major surgery, donated or lost 1 unit of blood, or participated in another investigational study within 4 weeks prior to the study
  • Type 1 hypersensitivity or idiosyncratic reactions to azole agents
  • Significant multiple or severe allergies, or has had an anaphylactic reaction or significant intolerability to drugs or food
  • Moderate or severe liver dysfunction
  • Chronic active hepatitis, cirrhosis, Hepatocellular Carcinoma (HCC), or other hepatic disease caused by a virus
  • Previous electrocardiogram with a prolonged QTc interval
  • Prior enrollment in this study or other posaconazole studies within 90 days of study entry
  • Eastern Cooperative Oncology Group (ECOG) performance status was >2 prior to induction chemotherapy for the underlying disease
  • Known or suspected Gilbert's disease.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PosaconazolePosaconazoleAll participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
Primary Outcome Measures
NameTimeMethod
Steady State Minimum Concentration (ssCmin) of POS of Serial PK (Subgroup 1) on Day 10Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Cmin is defined as the minimum concentration of POS in plasma.

Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.

Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only.

Steady State Maximum Concentration (ssCmax) of POS of Serial PK (Subgroup 1) on Day 10Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Cmax is defined as the maximum concentration of POS in plasma.

Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.

Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only.

Steady-state Area Under the Concentration-time Curve (ssAUC0-24hr) of POS of Serial PK (Subgroup 1) on Day 10Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. AUC0-24 is defined as area under the plasma concentration-time curve from time 0 extrapolated to 24 hours.

Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.

Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only.

Steady State (ss) Average Concentration (Cavg) of Posaconazole of Serial PK (Subgroup 1) on Day 10Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Characterization of the pharmacokinetics (PK) parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Steady-state Cavg, where Cavg is defined as AUC0-24hr divided by the dosing interval.

Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.

Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only.

Percentage of Participants With ssCavg ≥500 ng/mL of Serial PK (Subgroup 1) on Day 10Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Steady-state Cavg, where Cavg is defined as AUC0-24hr divided by the dosing interval. The percentage of participants with ssCavg ≥500 ng/mL are presented.

Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.

Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only.

POS Plasma Trough Concentrations in the Serial PK and Sparse PK SubgroupsDay 3, Day 6, Day 10, Day 15, Day 22, Day 28

Pre-dose plasma trough concentrations by study day between serial PK and Sparse PK - where serial PK is defined as multiple serial blood sampling of more than 6 timepoints; and sparse PK is defined as few blood samples taken and single or limited timepoints

Time to Steady-state Maximum Concentration (ssTmax) of POS of Serial PK (Subgroup 1) on Day 10Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. Tmax is defined as the time it takes to achieve maximum concentration of POS in plasma.

Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.

Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only.

Total Body Clearance (CL) of POS of Serial PK (Subgroup 1) on Day 10Serial PK (Subgroup 1) on Day 10 at pre-dose, 1 hr. post start of infusion (SOI), end of infusion (EOI), 15 min. after EOI and 4, 8, 12, 24 hours post SOI

Characterization of the PK parameters of POS determined from plasma samples taken at steady-state after receiving IV administration of 300 mg POS twice a day (BID) on Day 1 and then 300 mg POS QD until at least Day 10. CL is defined as the time it takes for POS to be completely removed from the body's blood stream.

Subgroup 1 - Serial PK, multiple same-day blood draw, performed specifically for determination of PK parameters of Cavg, AUC, Cmin, Cmax, Tmax and Total Body Clearance in addition to plasma trough determination.

Subgroup 2 - Sparse PK, once a day blood draw, performed for plasma trough determination only.

Secondary Outcome Measures
NameTimeMethod
Adverse Events (AEs)Up to 58 days

Number of participants with one or more AEs where AEs are defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Discontinuations Due to an AEUp to 28 days

Number of participants discontinued from study medication due to an AE where AEs are defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Medically Significant Changes in Clinical Laboratory Results - Lab ValuesUp to 28 days

The number of participants with clinical laboratory values outside of normal range

Medically Significant Changes in Clinical Laboratory Results - Vital SignsUp to 28 days

The number of participants with values of vital signs outside of normal range

Survival StatusUp to 98 days

Survival assessment as to whether a participant is alive or dead, included all participants who died - 2 during study treatment, 1 during safety follow-up, 2 during survival follow-up (Day 60 to 70 post dose), and 1 participant who died during serious AE (SAE) follow-up at 97 days after first dose but was beyond the safety and the survival follow-up period

Participants With Invasive Fungal Infection (IFI)Up to 28 days

Number of participants with possible, probable, or proven IFI observed during the whole study period

Trial Locations

Locations (7)

Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 0001)

🇨🇳

Tianjin, China

Shanghai General Hospital ( Site 0007)

🇨🇳

Shanghai, China

Peking University Third Hospital ( Site 0009)

🇨🇳

Beijing, China

The First Affiliated Hospital of Soochow University ( Site 0004)

🇨🇳

Suzhou, Jiangsu, China

Peking Union Medical College Hospital ( Site 0006)

🇨🇳

Beijing, China

Guangdong General Hospital, Guangdong Academy of Medical Science ( Site 0002)

🇨🇳

Guangzhou, Guangdong, China

Peking University People's Hospital ( Site 0008)

🇨🇳

Beijing, China

© Copyright 2025. All Rights Reserved by MedPath